Show simple item record

dc.contributor.authorAdams, Richard A.
dc.contributor.authorFisher, David J.
dc.contributor.authorGraham, Janet
dc.contributor.authorSeligmann, Jenny F.
dc.contributor.authorSeymour, Matthew
dc.contributor.authorKaplan, Richard
dc.contributor.authorYates, Emma
dc.contributor.authorParmar, Mahesh
dc.contributor.authorRichman, Susan D.
dc.contributor.authorQuirke, Philip
dc.contributor.authorButler, Rachel
dc.contributor.authorBrown, Ewan
dc.contributor.authorCollinson, Fiona
dc.contributor.authorFalk, Stephen
dc.contributor.authorWasan, Harpreet
dc.contributor.authorShiu, Kai-Keen
dc.contributor.authorMiddleton, Gary
dc.contributor.authorSamuel, Leslie
dc.contributor.authorWilson, Richard H.
dc.contributor.authorBrown, Louise C.
dc.contributor.authorMaughan, Timothy S.
dc.contributor.authorFOCUS Trial Collaboration
dc.date.accessioned2021-11-24T09:43:01Z
dc.date.available2021-11-24T09:43:01Z
dc.date.issued2021-11-20
dc.identifier.citationAdams , R A , Fisher , D J , Graham , J , Seligmann , J F , Seymour , M , Kaplan , R , Yates , E , Parmar , M , Richman , S D , Quirke , P , Butler , R , Brown , E , Collinson , F , Falk , S , Wasan , H , Shiu , K-K , Middleton , G , Samuel , L , Wilson , R H , Brown , L C , Maughan , T S & FOCUS Trial Collaboration 2021 , ' Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial ' , Journal of Clinical Oncology , vol. 39 , no. 33 , JCO.21.01436 , pp. 3693-3704 . https://doi.org/10.1200/JCO.21.01436en
dc.identifier.issn0732-183X
dc.identifier.otherPURE: 200470280
dc.identifier.otherPURE UUID: da21a725-c787-4fe5-9564-1a5a30dccfa4
dc.identifier.otherRIS: urn:DD8C999877AC6619E48FC8DE1CC26E8B
dc.identifier.otherORCID: /0000-0002-8402-8670/work/100345920
dc.identifier.otherPubMed: 34516759
dc.identifier.urihttps://hdl.handle.net/2164/17553
dc.descriptionSUPPORT Supported by Cancer Research UK and the National Institute for Health Research (NIHR).en
dc.format.extent42
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Oncologyen
dc.rights© 2021 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleCapecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1200/JCO.21.01436


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record